Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vir Biotechnology price target raised to $61 from $44 at Barclays » 07:29
08/12/20
08/12
07:29
08/12/20
07:29
VIR

Vir Biotechnology

$52.70 /

-0.49 (-0.92%)

, GILD

Gilead

$68.10 /

-0.43 (-0.63%)

Barclays analyst Gena…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
GILD Gilead
$68.10 /

-0.43 (-0.63%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

  • 08
    Jul
  • 11
    Oct
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

Conference/Events
Canaccord to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
ACIW

ACI Worldwide

$30.73 /

+0.21 (+0.69%)

, AGIO

Agios Pharmaceuticals

$40.42 /

-1.705 (-4.05%)

, BCEL

Atreca

$13.80 /

-0.16 (-1.15%)

, BLUE

Bluebird Bio

$62.55 /

-3.13 (-4.77%)

, CRTX

Cortexyme

$43.69 /

-0.87 (-1.95%)

, BMRN

BioMarin

$116.64 /

-1.63 (-1.38%)

, PEGA

Pegasystems

$114.50 /

+0.91 (+0.80%)

, ONCY

Oncolytics

$1.86 /

-0.07 (-3.63%)

, XNCR

Xencor

$32.04 /

+0.35 (+1.10%)

, VAPO

Vapotherm

$29.03 /

-0.08 (-0.27%)

, TCMD

Tactile Systems

$38.00 /

-0.34 (-0.89%)

, MIRM

Mirum Pharmaceuticals

$26.06 /

-0.785 (-2.92%)

, MMSI

Merit Medical

$44.07 /

+0.39 (+0.89%)

, GAN

Gan Limited

$19.58 /

-0.25 (-1.26%)

, GH

Guardant Health

$81.65 /

-4.3 (-5.00%)

, HALO

Halozyme

$28.20 /

-0.46 (-1.61%)

, LOV

Spark Networks

$5.16 /

+0.02 (+0.39%)

, SPNE

SeaSpine

$13.96 /

-0.06 (-0.43%)

, CUB

Cubic

$47.11 /

+0.36 (+0.77%)

, CUTR

Cutera

$14.64 /

+0.37 (+2.59%)

, CRY

CryoLife

$20.99 /

-0.4 (-1.87%)

40th Annual Global Growth…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XNCR Xencor
$32.04 /

+0.35 (+1.10%)

VAPO Vapotherm
$29.03 /

-0.08 (-0.27%)

TCMD Tactile Systems
$38.00 /

-0.34 (-0.89%)

SPNE SeaSpine
$13.96 /

-0.06 (-0.43%)

PEGA Pegasystems
$114.50 /

+0.91 (+0.80%)

ONCY Oncolytics
$1.86 /

-0.07 (-3.63%)

MMSI Merit Medical
$44.07 /

+0.39 (+0.89%)

MIRM Mirum Pharmaceuticals
$26.06 /

-0.785 (-2.92%)

HALO Halozyme
$28.20 /

-0.46 (-1.61%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

GAN Gan Limited
$19.58 /

-0.25 (-1.26%)

CUTR Cutera
$14.64 /

+0.37 (+2.59%)

CUB Cubic
$47.11 /

+0.36 (+0.77%)

CRY CryoLife
$20.99 /

-0.4 (-1.87%)

CRTX Cortexyme
$43.69 /

-0.87 (-1.95%)

BMRN BioMarin
$116.64 /

-1.63 (-1.38%)

BLUE Bluebird Bio
$62.55 /

-3.13 (-4.77%)

BCEL Atreca
$13.80 /

-0.16 (-1.15%)

AGIO Agios Pharmaceuticals
$40.42 /

-1.705 (-4.05%)

ACIW ACI Worldwide
$30.73 /

+0.21 (+0.69%)

ACIW ACI Worldwide
$30.73 /

+0.21 (+0.69%)

08/07/20 Canaccord
ACI Worldwide price target raised to $40 from $35 at Canaccord
07/07/20 Canaccord
ACI Worldwide product portfolio increases confidence, says Canaccord
05/29/20 Needham
ACI Worldwide initiated with a Buy at Needham
05/08/20 Canaccord
ACI Worldwide price target lowered to $35 from $44 at Canaccord
AGIO Agios Pharmaceuticals
$40.42 /

-1.705 (-4.05%)

06/23/20 Piper Sandler
Agios Pharmaceuticals should be owned through year-end, says Piper Sandler
06/15/20 Guggenheim
Agios Pharmaceuticals price target raised to $66 from $60 at Guggenheim
06/15/20 Citi
Agios Pharmaceuticals price target raised to $75 from $64 at Citi
06/12/20 Piper Sandler
Agios Pharmaceuticals price target raised to $80 from $70 at Piper Sandler
BCEL Atreca
$13.80 /

-0.16 (-1.15%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
BLUE Bluebird Bio
$62.55 /

-3.13 (-4.77%)

08/06/20 Wedbush
Bluebird Bio price target lowered to $81 from $89 at Wedbush
06/12/20 Piper Sandler
Bluebird Bio update 'modestly positive,' says Piper Sandler
06/10/20 Stifel
Stifel says Bluebird setup 'downside biased,' Crispr's 'upside biased' into EHA
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
CRTX Cortexyme
$43.69 /

-0.87 (-1.95%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
BMRN BioMarin
$116.64 /

-1.63 (-1.38%)

08/05/20 SVB Leerink
BioMarin price target raised to $140 from $130 at SVB Leerink
08/05/20 Barclays
BioMarin price target raised to $135 from $125 at Barclays
08/05/20 JPMorgan
BioMarin price target raised to $156 from $140 at JPMorgan
08/05/20 Cantor Fitzgerald
BioMarin shares can re-rate further despite 42% rally, says Cantor Fitzgerald
PEGA Pegasystems
$114.50 /

+0.91 (+0.80%)

07/29/20 Rosenblatt
Pegasystems price target raised to $125 from $120 at Rosenblatt
07/29/20 JMP Securities
Pegasystems price target raised to $126 from $109 at JMP Securities
07/07/20 Barclays
Pegasystems initiated with an Equal Weight at Barclays
07/06/20 Wedbush
Pegasystems, Splunk removed from Best Ideas List at Wedbush
ONCY Oncolytics
$1.86 /

-0.07 (-3.63%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
XNCR Xencor
$32.04 /

+0.35 (+1.10%)

06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
VAPO Vapotherm
$29.03 /

-0.08 (-0.27%)

07/13/20 BTIG
Vapotherm price target raised to $53 from $32 at BTIG
06/05/20 Canaccord
Vapotherm price target raised to $34 from $30 at Canaccord
05/06/20 Canaccord
Vapotherm price target raised to $30 from $20 at Canaccord
04/14/20 Canaccord
Vapotherm price target raised to $20 from $14 at Canaccord
TCMD Tactile Systems
$38.00 /

-0.34 (-0.89%)

08/03/20 Piper Sandler
Tactile Systems disrupted by pandemic in Q2, says Piper Sandler
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
04/07/20 BTIG
Tactile Systems price target lowered to $63 from $72 at BTIG
04/06/20 Piper Sandler
Piper Sandler remains 'constructive' on Tactile Systems after 'solid' Q1 results
MIRM Mirum Pharmaceuticals
$26.06 /

-0.785 (-2.92%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MMSI Merit Medical
$44.07 /

+0.39 (+0.89%)

07/30/20 Barrington
Merit Medical price target raised to $54 from $49 at Barrington
07/30/20 Piper Sandler
Merit Medical price target raised to $55 from $50 at Piper Sandler
05/27/20 Barrington
Merit Medical price target raised to $49 from $42 at Barrington
05/26/20 Piper Sandler
Piper Sandler positive on Merit Medical's Starboard agreement on board members
GAN Gan Limited
$19.58 /

-0.25 (-1.26%)

07/17/20 Northland
Gan Limited initiated with an Outperform at Northland
07/14/20 Craig-Hallum
NJ sports betting up despite no sports, iGaming also strong, says Craig-Hallum
06/18/20 Craig-Hallum
Gan Limited price target raised to $28 from $25 at Craig-Hallum
06/18/20 B. Riley FBR
Gan Limited price target raised to $28.50 from $24 at B. Riley FBR
GH Guardant Health
$81.65 /

-4.3 (-5.00%)

08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
HALO Halozyme
$28.20 /

-0.46 (-1.61%)

08/11/20 BMO Capital
Halozyme price target raised to $43 from $35 at BMO Capital
08/11/20 Wells Fargo
Halozyme price target raised to $39 from $31 at Wells Fargo
07/02/20 Piper Sandler
Halozyme price target raised to $31 from $28 at Piper Sandler
07/01/20 Benchmark
Benchmark starts Halozyme at Buy with $39 price target
LOV Spark Networks
$5.16 /

+0.02 (+0.39%)

04/30/20 B. Riley FBR
Spark Networks price target lowered to $7.50 from $11 at B. Riley FBR
04/21/20 B. Riley FBR
Spark Networks price target lowered to $11 from $17.50 at B. Riley FBR
08/30/19 Canaccord
Spark Networks current valuation is just too compelling, says Canaccord
SPNE SeaSpine
$13.96 /

-0.06 (-0.43%)

08/05/20 Piper Sandler
SeaSpine remains 'must own SMID name' at Piper Sandler
06/16/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
04/07/20 Wells Fargo
SeaSpine upgraded to Equal Weight on valuation at Wells Fargo
CUB Cubic
$47.11 /

+0.36 (+0.77%)

08/06/20 Canaccord
Cubic price target raised to $58 from $48 at Canaccord
07/28/20 JPMorgan
Cubic price target raised to $58 from $53 at JPMorgan
07/16/20 Needham
Cubic price target raised to $52 from $49 at Needham
05/20/20 RBC Capital
RBC Capital starts Cubic at Sector Perform with $37 price target
CUTR Cutera
$14.64 /

+0.37 (+2.59%)

08/07/20 Piper Sandler
Cutera should be bought at these 'depressed levels,' says Piper Sandler
05/05/20
Fly Intel: Top five analyst upgrades
05/05/20 Stifel
Cutera upgraded to Buy from Hold at Stifel
04/22/20 Piper Sandler
Cutera initiated with an Overweight at Piper Sandler
CRY CryoLife
$20.99 /

-0.4 (-1.87%)

05/01/20 Lake Street
CryoLife price target raised to $27 from $22 at Lake Street
04/03/20 Lake Street
CryoLife price target lowered to $22 from $38 at Lake Street
04/02/20 Lake Street
CryoLife should emerge stronger in coming years, says Lake Street
04/02/20 Needham
CryoLife price target lowered to $29 from $38 at Needham
XNCR Xencor
$32.04 /

+0.35 (+1.10%)

VAPO Vapotherm
$29.03 /

-0.08 (-0.27%)

TCMD Tactile Systems
$38.00 /

-0.34 (-0.89%)

SPNE SeaSpine
$13.96 /

-0.06 (-0.43%)

PEGA Pegasystems
$114.50 /

+0.91 (+0.80%)

MMSI Merit Medical
$44.07 /

+0.39 (+0.89%)

MIRM Mirum Pharmaceuticals
$26.06 /

-0.785 (-2.92%)

HALO Halozyme
$28.20 /

-0.46 (-1.61%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

GAN Gan Limited
$19.58 /

-0.25 (-1.26%)

CUTR Cutera
$14.64 /

+0.37 (+2.59%)

CUB Cubic
$47.11 /

+0.36 (+0.77%)

CRY CryoLife
$20.99 /

-0.4 (-1.87%)

CRTX Cortexyme
$43.69 /

-0.87 (-1.95%)

BMRN BioMarin
$116.64 /

-1.63 (-1.38%)

BLUE Bluebird Bio
$62.55 /

-3.13 (-4.77%)

BCEL Atreca
$13.80 /

-0.16 (-1.15%)

AGIO Agios Pharmaceuticals
$40.42 /

-1.705 (-4.05%)

ACIW ACI Worldwide
$30.73 /

+0.21 (+0.69%)

  • 16
    Jul
  • 02
    Jun
  • 19
    May
  • 07
    May
  • 05
    May
  • 17
    Apr
  • 06
    Feb
  • 08
    Jan
  • 09
    Jan
  • 08
    Nov
  • 14
    Aug
GAN Gan Limited
$19.58 /

-0.25 (-1.26%)

CUB Cubic
$47.11 /

+0.36 (+0.77%)

XNCR Xencor
$32.04 /

+0.35 (+1.10%)

VAPO Vapotherm
$29.03 /

-0.08 (-0.27%)

MMSI Merit Medical
$44.07 /

+0.39 (+0.89%)

HALO Halozyme
$28.20 /

-0.46 (-1.61%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

CUTR Cutera
$14.64 /

+0.37 (+2.59%)

CUB Cubic
$47.11 /

+0.36 (+0.77%)

BMRN BioMarin
$116.64 /

-1.63 (-1.38%)

BLUE Bluebird Bio
$62.55 /

-3.13 (-4.77%)

BCEL Atreca
$13.80 /

-0.16 (-1.15%)

AGIO Agios Pharmaceuticals
$40.42 /

-1.705 (-4.05%)

VAPO Vapotherm
$29.03 /

-0.08 (-0.27%)

GAN Gan Limited
$19.58 /

-0.25 (-1.26%)

BMRN BioMarin
$116.64 /

-1.63 (-1.38%)

Yesterday
Conference/Events
Canaccord to hold a virtual conference » 08:28
08/11/20
08/11
08:28
08/11/20
08:28
ACIW

ACI Worldwide

$30.52 /

+0.01 (+0.03%)

, AGIO

Agios Pharmaceuticals

$42.12 /

-1.08 (-2.50%)

, BCEL

Atreca

$13.96 /

+0.62 (+4.65%)

, BLUE

Bluebird Bio

$65.68 /

+2.26 (+3.56%)

, CRTX

Cortexyme

$44.56 /

+0.75 (+1.71%)

, BMRN

BioMarin

$118.27 /

-0.44 (-0.37%)

, PEGA

Pegasystems

$113.59 /

-1.09 (-0.95%)

, ONCY

Oncolytics

$1.93 /

+0.035 (+1.85%)

, XNCR

Xencor

$31.69 /

-0.51 (-1.58%)

, VAPO

Vapotherm

$29.11 /

-1.45 (-4.74%)

, TCMD

Tactile Systems

$38.34 /

+0.8 (+2.13%)

, MIRM

Mirum Pharmaceuticals

$26.84 /

+1.82 (+7.27%)

, MMSI

Merit Medical

$43.68 /

-1.05 (-2.35%)

, GAN

Gan Limited

$19.83 /

-0.47 (-2.32%)

, GH

Guardant Health

$85.95 /

+0.16 (+0.19%)

, HALO

Halozyme

$28.66 /

-0.26 (-0.90%)

, LOV

Spark Networks

$5.14 /

-0.33 (-6.03%)

, SPNE

SeaSpine

$14.02 /

-0.8 (-5.40%)

, CUB

Cubic

$46.75 /

+1.865 (+4.16%)

, CUTR

Cutera

$14.27 /

-0.6 (-4.03%)

, CRY

CryoLife

$21.39 /

+0.32 (+1.52%)

40th Annual Global Growth…

40th Annual Global Growth Virtual Conference will be held on August 11-13.

ShowHide Related Items >><<
XNCR Xencor
$31.69 /

-0.51 (-1.58%)

VAPO Vapotherm
$29.11 /

-1.45 (-4.74%)

TCMD Tactile Systems
$38.34 /

+0.8 (+2.13%)

SPNE SeaSpine
$14.02 /

-0.8 (-5.40%)

PEGA Pegasystems
$113.59 /

-1.09 (-0.95%)

ONCY Oncolytics
$1.93 /

+0.035 (+1.85%)

MMSI Merit Medical
$43.68 /

-1.05 (-2.35%)

MIRM Mirum Pharmaceuticals
$26.84 /

+1.82 (+7.27%)

HALO Halozyme
$28.66 /

-0.26 (-0.90%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

GAN Gan Limited
$19.83 /

-0.47 (-2.32%)

CUTR Cutera
$14.27 /

-0.6 (-4.03%)

CUB Cubic
$46.75 /

+1.865 (+4.16%)

CRY CryoLife
$21.39 /

+0.32 (+1.52%)

CRTX Cortexyme
$44.56 /

+0.75 (+1.71%)

BMRN BioMarin
$118.27 /

-0.44 (-0.37%)

BLUE Bluebird Bio
$65.68 /

+2.26 (+3.56%)

BCEL Atreca
$13.96 /

+0.62 (+4.65%)

AGIO Agios Pharmaceuticals
$42.12 /

-1.08 (-2.50%)

ACIW ACI Worldwide
$30.52 /

+0.01 (+0.03%)

ACIW ACI Worldwide
$30.52 /

+0.01 (+0.03%)

08/07/20 Canaccord
ACI Worldwide price target raised to $40 from $35 at Canaccord
07/07/20 Canaccord
ACI Worldwide product portfolio increases confidence, says Canaccord
05/29/20 Needham
ACI Worldwide initiated with a Buy at Needham
05/08/20 Canaccord
ACI Worldwide price target lowered to $35 from $44 at Canaccord
AGIO Agios Pharmaceuticals
$42.12 /

-1.08 (-2.50%)

06/23/20 Piper Sandler
Agios Pharmaceuticals should be owned through year-end, says Piper Sandler
06/15/20 Guggenheim
Agios Pharmaceuticals price target raised to $66 from $60 at Guggenheim
06/15/20 Citi
Agios Pharmaceuticals price target raised to $75 from $64 at Citi
06/12/20 Piper Sandler
Agios Pharmaceuticals price target raised to $80 from $70 at Piper Sandler
BCEL Atreca
$13.96 /

+0.62 (+4.65%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
BLUE Bluebird Bio
$65.68 /

+2.26 (+3.56%)

08/06/20 Wedbush
Bluebird Bio price target lowered to $81 from $89 at Wedbush
06/12/20 Piper Sandler
Bluebird Bio update 'modestly positive,' says Piper Sandler
06/10/20 Stifel
Stifel says Bluebird setup 'downside biased,' Crispr's 'upside biased' into EHA
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
CRTX Cortexyme
$44.56 /

+0.75 (+1.71%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
BMRN BioMarin
$118.27 /

-0.44 (-0.37%)

08/05/20 SVB Leerink
BioMarin price target raised to $140 from $130 at SVB Leerink
08/05/20 Barclays
BioMarin price target raised to $135 from $125 at Barclays
08/05/20 JPMorgan
BioMarin price target raised to $156 from $140 at JPMorgan
08/05/20 Cantor Fitzgerald
BioMarin shares can re-rate further despite 42% rally, says Cantor Fitzgerald
PEGA Pegasystems
$113.59 /

-1.09 (-0.95%)

07/29/20 Rosenblatt
Pegasystems price target raised to $125 from $120 at Rosenblatt
07/29/20 JMP Securities
Pegasystems price target raised to $126 from $109 at JMP Securities
07/07/20 Barclays
Pegasystems initiated with an Equal Weight at Barclays
07/06/20 Wedbush
Pegasystems, Splunk removed from Best Ideas List at Wedbush
ONCY Oncolytics
$1.93 /

+0.035 (+1.85%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
XNCR Xencor
$31.69 /

-0.51 (-1.58%)

06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
VAPO Vapotherm
$29.11 /

-1.45 (-4.74%)

07/13/20 BTIG
Vapotherm price target raised to $53 from $32 at BTIG
06/05/20 Canaccord
Vapotherm price target raised to $34 from $30 at Canaccord
05/06/20 Canaccord
Vapotherm price target raised to $30 from $20 at Canaccord
04/14/20 Canaccord
Vapotherm price target raised to $20 from $14 at Canaccord
TCMD Tactile Systems
$38.34 /

+0.8 (+2.13%)

08/03/20 Piper Sandler
Tactile Systems disrupted by pandemic in Q2, says Piper Sandler
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
04/07/20 BTIG
Tactile Systems price target lowered to $63 from $72 at BTIG
04/06/20 Piper Sandler
Piper Sandler remains 'constructive' on Tactile Systems after 'solid' Q1 results
MIRM Mirum Pharmaceuticals
$26.84 /

+1.82 (+7.27%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MMSI Merit Medical
$43.68 /

-1.05 (-2.35%)

07/30/20 Barrington
Merit Medical price target raised to $54 from $49 at Barrington
07/30/20 Piper Sandler
Merit Medical price target raised to $55 from $50 at Piper Sandler
05/27/20 Barrington
Merit Medical price target raised to $49 from $42 at Barrington
05/26/20 Piper Sandler
Piper Sandler positive on Merit Medical's Starboard agreement on board members
GAN Gan Limited
$19.83 /

-0.47 (-2.32%)

07/17/20 Northland
Gan Limited initiated with an Outperform at Northland
07/14/20 Craig-Hallum
NJ sports betting up despite no sports, iGaming also strong, says Craig-Hallum
06/18/20 Craig-Hallum
Gan Limited price target raised to $28 from $25 at Craig-Hallum
06/18/20 B. Riley FBR
Gan Limited price target raised to $28.50 from $24 at B. Riley FBR
GH Guardant Health
$85.95 /

+0.16 (+0.19%)

08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
HALO Halozyme
$28.66 /

-0.26 (-0.90%)

07/02/20 Piper Sandler
Halozyme price target raised to $31 from $28 at Piper Sandler
07/01/20 Benchmark
Benchmark starts Halozyme at Buy with $39 price target
07/01/20 Benchmark
Halozyme initiated with a Buy at Benchmark
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
LOV Spark Networks
$5.14 /

-0.33 (-6.03%)

04/30/20 B. Riley FBR
Spark Networks price target lowered to $7.50 from $11 at B. Riley FBR
04/21/20 B. Riley FBR
Spark Networks price target lowered to $11 from $17.50 at B. Riley FBR
08/30/19 Canaccord
Spark Networks current valuation is just too compelling, says Canaccord
SPNE SeaSpine
$14.02 /

-0.8 (-5.40%)

08/05/20 Piper Sandler
SeaSpine remains 'must own SMID name' at Piper Sandler
06/16/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
04/07/20 Wells Fargo
SeaSpine upgraded to Equal Weight on valuation at Wells Fargo
CUB Cubic
$46.75 /

+1.865 (+4.16%)

08/06/20 Canaccord
Cubic price target raised to $58 from $48 at Canaccord
07/28/20 JPMorgan
Cubic price target raised to $58 from $53 at JPMorgan
07/16/20 Needham
Cubic price target raised to $52 from $49 at Needham
05/20/20 RBC Capital
RBC Capital starts Cubic at Sector Perform with $37 price target
CUTR Cutera
$14.27 /

-0.6 (-4.03%)

08/07/20 Piper Sandler
Cutera should be bought at these 'depressed levels,' says Piper Sandler
05/05/20
Fly Intel: Top five analyst upgrades
05/05/20 Stifel
Cutera upgraded to Buy from Hold at Stifel
04/22/20 Piper Sandler
Cutera initiated with an Overweight at Piper Sandler
CRY CryoLife
$21.39 /

+0.32 (+1.52%)

05/01/20 Lake Street
CryoLife price target raised to $27 from $22 at Lake Street
04/03/20 Lake Street
CryoLife price target lowered to $22 from $38 at Lake Street
04/02/20 Lake Street
CryoLife should emerge stronger in coming years, says Lake Street
04/02/20 Needham
CryoLife price target lowered to $29 from $38 at Needham
XNCR Xencor
$31.69 /

-0.51 (-1.58%)

VAPO Vapotherm
$29.11 /

-1.45 (-4.74%)

TCMD Tactile Systems
$38.34 /

+0.8 (+2.13%)

SPNE SeaSpine
$14.02 /

-0.8 (-5.40%)

PEGA Pegasystems
$113.59 /

-1.09 (-0.95%)

MMSI Merit Medical
$43.68 /

-1.05 (-2.35%)

MIRM Mirum Pharmaceuticals
$26.84 /

+1.82 (+7.27%)

HALO Halozyme
$28.66 /

-0.26 (-0.90%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

GAN Gan Limited
$19.83 /

-0.47 (-2.32%)

CUTR Cutera
$14.27 /

-0.6 (-4.03%)

CUB Cubic
$46.75 /

+1.865 (+4.16%)

CRY CryoLife
$21.39 /

+0.32 (+1.52%)

CRTX Cortexyme
$44.56 /

+0.75 (+1.71%)

BMRN BioMarin
$118.27 /

-0.44 (-0.37%)

BLUE Bluebird Bio
$65.68 /

+2.26 (+3.56%)

BCEL Atreca
$13.96 /

+0.62 (+4.65%)

AGIO Agios Pharmaceuticals
$42.12 /

-1.08 (-2.50%)

ACIW ACI Worldwide
$30.52 /

+0.01 (+0.03%)

  • 16
    Jul
  • 02
    Jun
  • 19
    May
  • 07
    May
  • 05
    May
  • 17
    Apr
  • 06
    Feb
  • 08
    Jan
  • 09
    Jan
  • 08
    Nov
  • 14
    Aug
GAN Gan Limited
$19.83 /

-0.47 (-2.32%)

CUB Cubic
$46.75 /

+1.865 (+4.16%)

XNCR Xencor
$31.69 /

-0.51 (-1.58%)

VAPO Vapotherm
$29.11 /

-1.45 (-4.74%)

MMSI Merit Medical
$43.68 /

-1.05 (-2.35%)

HALO Halozyme
$28.66 /

-0.26 (-0.90%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

CUTR Cutera
$14.27 /

-0.6 (-4.03%)

CUB Cubic
$46.75 /

+1.865 (+4.16%)

BMRN BioMarin
$118.27 /

-0.44 (-0.37%)

BLUE Bluebird Bio
$65.68 /

+2.26 (+3.56%)

BCEL Atreca
$13.96 /

+0.62 (+4.65%)

AGIO Agios Pharmaceuticals
$42.12 /

-1.08 (-2.50%)

VAPO Vapotherm
$29.11 /

-1.45 (-4.74%)

GAN Gan Limited
$19.83 /

-0.47 (-2.32%)

BMRN BioMarin
$118.27 /

-0.44 (-0.37%)

Hot Stocks
Gilead says China NMPA approves Truvada for PrEP » 08:14
08/11/20
08/11
08:14
08/11/20
08:14
GILD

Gilead

$68.53 /

-0.88 (-1.27%)

Gilead said in a release,…

Gilead said in a release, "Gilead Sciences announced that the China National Medical Products Administration, or NMPA, has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF). In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis, or PrEP, to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. Truvada for PrEP should be taken once daily and used together with safer sex practices. Individuals must have a negative HIV-1 test immediately prior to initiating Truvada for PrEP."

ShowHide Related Items >><<
GILD Gilead
$68.53 /

-0.88 (-1.27%)

GILD Gilead
$68.53 /

-0.88 (-1.27%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
GILD Gilead
$68.53 /

-0.88 (-1.27%)

GILD Gilead
$68.53 /

-0.88 (-1.27%)

GILD Gilead
$68.53 /

-0.88 (-1.27%)

GILD Gilead
$68.53 /

-0.88 (-1.27%)

Monday
Hot Stocks
Gilead submits NDA to FDA for Veklury for COVID-19 treatment » 11:02
08/10/20
08/10
11:02
08/10/20
11:02
GILD

Gilead

$68.48 /

-0.93 (-1.34%)

Gilead Sciences announced…

Gilead Sciences announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for Veklury, an investigational antiviral for the treatment of patients with COVID-19. Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. The filing is the final tier of the rolling NDA submission that was initiated on April 8, 2020. The filing is supported by data from two randomized, open-label, multi-center Phase 3 clinical studies of Veklury conducted by Gilead and the Phase 3 randomized, placebo-controlled study of Veklury conducted by the National Institute of Allergy and Infectious Diseases. These studies demonstrated that treatment with Veklury led to faster time to recovery compared with placebo and that a 5-day or 10-day treatment duration led to similar clinical improvement. Across studies, Veklury was generally well-tolerated in both the 5-day and 10-day treatment groups, with no new safety signals identified. Veklury has been approved by multiple regulatory authorities around the world, including in the European Union and Japan. In countries where Veklury has not been approved, including the United States, Veklury is an investigational drug and the safety and efficacy of remdesivir have not been established. Please see below for additional important warnings and information about the authorized use of Veklury in the United States.

ShowHide Related Items >><<
GILD Gilead
$68.48 /

-0.93 (-1.34%)

GILD Gilead
$68.48 /

-0.93 (-1.34%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
GILD Gilead
$68.48 /

-0.93 (-1.34%)

GILD Gilead
$68.48 /

-0.93 (-1.34%)

GILD Gilead
$68.48 /

-0.93 (-1.34%)

GILD Gilead
$68.48 /

-0.93 (-1.34%)

Conference/Events
FDA PDUFA Date for Gilead Axicabtagene Ciloleucel (ZUMA-2) is August 10, 2020  08:36
08/10/20
08/10
08:36
08/10/20
08:36
GILD

Gilead

$69.41 /

+0.61 (+0.89%)

 
ShowHide Related Items >><<
GILD Gilead
$69.41 /

+0.61 (+0.89%)

GILD Gilead
$69.41 /

+0.61 (+0.89%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
GILD Gilead
$69.41 /

+0.61 (+0.89%)

GILD Gilead
$69.41 /

+0.61 (+0.89%)

GILD Gilead
$69.41 /

+0.61 (+0.89%)

GILD Gilead
$69.41 /

+0.61 (+0.89%)

Friday
Syndicate
Gilead files automatic mixed securities shelf  16:04
08/07/20
08/07
16:04
08/07/20
16:04
GILD

Gilead

$69.31 /

+0.51 (+0.74%)

 
ShowHide Related Items >><<
GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

Hot Stocks
Pfizer announces agreement with Gilead to manufacture remdesivir » 08:05
08/07/20
08/07
08:05
08/07/20
08:05
PFE

Pfizer

$38.27 /

-0.18 (-0.47%)

, GILD

Gilead

$68.80 /

-0.19 (-0.28%)

Pfizer (PFE) said in a…

Pfizer (PFE) said in a release, "Pfizer announced a multi-year agreement with Gilead Sciences (GILD) to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer's McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem - from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions - to commit to work together in addressing the dire COVID-19 crisis."

ShowHide Related Items >><<
PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
GILD Gilead
$68.80 /

-0.19 (-0.28%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

Hot Stocks
Global Blood Therapeutics announces new employment inducement grants » 08:05
08/07/20
08/07
08:05
08/07/20
08:05
GBT

Global Blood Therapeutics

$64.02 /

-3.85 (-5.67%)

Global Blood Therapeutics…

Global Blood Therapeutics announced that on August 1, 2020, the compensation committee of GBT's board of directors granted seven new employees options to purchase an aggregate of 9,750 shares of the company's common stock with a per share exercise price of $67.48 and restricted stock units for an aggregate of 55,675 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan (the Plan). Pursuant to the Plan, the exercise price for the 9,750 shares of the company's common stock was the closing trading price on July 31, 2020, because there was no closing trading price on August 1, 2020.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$64.02 /

-3.85 (-5.67%)

GBT Global Blood Therapeutics
$64.02 /

-3.85 (-5.67%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
GBT Global Blood Therapeutics
$64.02 /

-3.85 (-5.67%)

GBT Global Blood Therapeutics
$64.02 /

-3.85 (-5.67%)

Recommendations
Iovance Biotherapeutics price target raised to $53 from $44 at Chardan » 08:00
08/07/20
08/07
08:00
08/07/20
08:00
IOVA

Iovance Biotherapeutics

$31.21 /

+0.33 (+1.07%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on Iovance Biotherapeutics to $53 from $44 and keeps a Buy rating on the shares after the company reported Q2 results and affirmed guidance for a BLA filing for lifileucel in melanoma by the end of the year. The analyst updated his model for the Q2 results and higher assumptions on pricing based in part on durability in melanoma, Livshits noted.

ShowHide Related Items >><<
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

05/29/20 Piper Sandler
Piper says Iovance data for lifileucel continue to 'mature favorably'
05/28/20 Piper Sandler
Iovance melanoma data 'fully supportive of approval,' says Piper Sandler
04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

  • 29
    May
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.